Edluar Shortage: What Providers and Prescribers Need to Know in 2026

Edluar (zolpidem tartrate sublingual tablets, 5 mg and 10 mg) occupies a narrow but clinically important niche in the insomnia treatment landscape. Approved for the short-term treatment of sleep-onset insomnia, Edluar's sublingual delivery mechanism provides faster absorption than swallowed tablets — making it a useful option for patients with difficulty swallowing or those who need rapid sleep onset.

However, Edluar's limited availability at most pharmacies creates ongoing clinical workflow challenges. This briefing gives prescribers and clinical staff a concise, up-to-date overview of the access landscape, prescribing considerations, and actionable steps to support patient adherence.

Current Availability Status (Early 2026)

Edluar is not currently listed in a formal shortage by the FDA Drug Shortage Database or the ASHP Drug Shortage Database. However, prescribers should be aware that this does not reflect the practical availability challenge their patients face.

Edluar is a low-volume, brand-name specialty product. The vast majority of chain pharmacies do not routinely stock it because automated inventory systems prioritize medications with higher prescription volume. Patients are frequently told their pharmacy doesn't carry Edluar, which does not mean the drug is unavailable — it means locating a stocking pharmacy requires more effort.

Why Edluar Is Structurally Hard to Access

Understanding the root causes helps providers counsel patients and set accurate expectations:

• Low formulary inclusion. Most commercial and Medicare Part D formularies classify Edluar as a non-preferred brand, with prior authorization or step therapy requirements. This reduces prescription volume and thus pharmacy stocking.
• DEA Schedule IV constraints. Zolpidem is a Schedule IV controlled substance. Pharmacies face DEA ordering limits for controlled substances, and low-demand specialty formulations like Edluar compete with higher-volume zolpidem products for those limits at chain pharmacies.
• Generic sublingual unavailability. While the FDA has approved a generic version of zolpidem sublingual, it has not achieved widespread commercial distribution. This means Edluar remains the brand-name-only option in this formulation — less likely to be stocked by cost-conscious pharmacy inventory systems.
• Manufacturer supply chain. Edluar is manufactured by Viatris. Unlike generic oral zolpidem (which has multiple manufacturers), Edluar has a single manufacturer, creating a single-source supply dependency. Any manufacturing disruption has a direct impact on pharmacy supply.

Prescribing Considerations for Edluar in 2026

When prescribing Edluar, the following clinical and access-related points are worth noting:

• Dosing is gender-differentiated. Per FDA guidance, the recommended dose for women is 5 mg sublingually at bedtime. For men, the dose is 5-10 mg. Maximum dose is 10 mg/day. Elderly patients: 5 mg regardless of gender.
• Next-morning impairment risk. FDA requires lower-dose recommendations for women due to higher zolpidem blood levels (up to 40% higher than men). Counsel all patients about next-morning impairment and the risk of driving within 8 hours of taking the medication.
• Complex sleep behavior black box warning. The FDA added a boxed warning to all sedative-hypnotics (including Edluar) for complex sleep behaviors — sleepwalking, sleep driving, sleep eating — which can be fatal. Edluar should not be prescribed to patients with a prior history of complex sleep behaviors with any sedative-hypnotic.
• Hepatic impairment. Zolpidem is hepatically metabolized. In patients with hepatic impairment, use the 5 mg dose and monitor for increased exposure.
• Drug interactions. Co-administration with CNS depressants (opioids, benzodiazepines, alcohol, tricyclics) increases sedation and respiratory depression risk. CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) increase zolpidem exposure; consider dose reduction. CYP3A4 inducers (rifampin, St. John's Wort) reduce efficacy.

Prior Authorization and Insurance Considerations

Most commercial and Medicare Part D plans require prior authorization or step therapy for Edluar. Step therapy typically requires documentation that the patient has tried and failed (or has a contraindication to) generic zolpidem IR.

When completing PA requests, clinical justification for the sublingual route is key — such as documented difficulty swallowing, a specific need for faster onset than oral formulations, or a prior documented failure or intolerance of oral zolpidem. Clear documentation of the clinical rationale significantly improves PA approval rates.

Clinical Alternatives When Edluar Is Unavailable

When Edluar is unavailable or not covered, consider these evidence-based alternatives based on patient profile:

• Generic zolpidem IR (oral): Same active ingredient, widely available, much lower cost (~$10-$20/month with coupon). First-line switch for most patients.
• Eszopiclone (Lunesta generic): Non-benzodiazepine hypnotic with FDA approval for longer-term use. Available in generic. Useful when chronic insomnia management is needed.
• Zaleplon (Sonata generic): Ultra-short half-life (~1 hour). Suitable for sleep-onset insomnia with minimal morning-after impairment. Can be used for middle-of-night awakening if 4+ hours remain.
• Trazodone (off-label): Not a controlled substance. Very affordable (<$10/month). Useful for patients with comorbid depression or those where controlled substance access is a barrier. Off-label for insomnia.
• Doxepin 3-6 mg (Silenor): Low-dose doxepin is FDA-approved for insomnia (sleep maintenance). Not a controlled substance. Useful for elderly patients.

Helping Patients Find Edluar in Stock

For patients who need to stay on Edluar, directing them to tools that can locate stocking pharmacies is a high-value clinical intervention. medfinder for Providers is a real-time pharmacy availability tool that contacts pharmacies on the patient's behalf and texts them results. This reduces patient frustration, call abandonment, and ultimately improves adherence for patients who need Edluar specifically.

Independent pharmacies are also often better positioned to stock or special-order Edluar than chain pharmacies. Recommending that patients call independent pharmacies first — and ask about special ordering — can resolve the access issue without requiring a therapeutic switch.

Key Takeaways for Providers

• Edluar is not in a formal FDA/ASHP shortage in 2026, but is structurally hard to find at most pharmacies
• Women's recommended dose is 5 mg; men's is 5-10 mg; max 10 mg/day; elderly 5 mg
• Boxed warning: complex sleep behaviors (discontinue if occurs)
• Most plans require PA or step therapy; document clinical rationale for sublingual route
• Direct patients to medfinder or independent pharmacies to locate Edluar without a switch
• Generic zolpidem IR, eszopiclone, or trazodone are the most practical alternatives when Edluar is unavailable